Archives des Highlights - Page 2 of 6

Immunotherapies (Immune Checkpoint Inhibitors, ICI) have become a powerful therapeutic strategy for treating a variety of cancers. It is a very exciting area, but with challenges. Indeed, the patients’ response to these therapies is often heterogeneous and not durable, with only 20 to 40% of patients actually responding. More

Resistance to anti-PD-1 immunotherapy can be attributed to the gut microbiome

Jun 23, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work

DOI: 10.1126/science.aan4236 DOI: 10.1126/science.aao3290 DOI: 10.1126/science.aan370Immunotherapies (Immune...

Vaiomer will participate in the next MetaGenoPolis meeting on June 27.

Vaiomer is taking part to « la deuxième édition de LA JOURNÉE DU MICROBIOTE»

Jun 22, 2023 | Highlights, News

Vaiomer is happy to announce its participation to "la deuxième édition de la journée microbiote de MetaGenopolis" on...

Numerous metagenomics-based studies have associated gut microbiota dysbiosis with the progression and resistance to immunotherapy of intestinal and non-intestinal cancers. more

Gut microbiota dysbiosis contributes to the tumorigenic process, even in extra-intestinal malignancies

Jun 12, 2023 | Highlights, Microbiomes & cancer, Vaiomer original work

doi: 10.1158/2159-8290.CD-21-0999Numerous metagenomics-based studies have associated gut microbiota dysbiosis with the...

Vaiomer and Physiogenex are proud to announce the launch of the TRANSBIOTIC project, to develop and validate mouse models with human microbiomes for evaluating therapies targeting metabolic and inflammatory diseases. Thanks La Région Occitanie-Pyrénées-Méditerranée for its support !

Mouse models with human microbiome

Apr 27, 2023 | Highlights, News

Physiogenex and Vaiomer Launch the TRANSBIOTIC project: A New Collaborative Research Project on mouse models...

Yde et al., explored the changes in the microbiota composition and metabolite levels induced by pre- and/or probiotic in an HFD mouse model. More

Metabolism and obesity: influence of prebiotics, probiotics and symbiotics on microbiomes and liver health

Apr 24, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work

doi: 10.1371/journal.pone.0260765Prebiotic, probiotic and symbiotic treatments affect intestinal and adipose tissue...

In this article, Ciocan and colleagues explored the blood microbiome and metabolome in patients with major depressive episodes (MDE) before and after treatment and compared them to healthy controls. More

Metabolism and Major Depression: Blood microbiome and metabolome exploration

Apr 24, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work

DOI: 10.1503/jpn.200159 Response to antidepressant is associated with blood microbiome and metabolome of patients with...

Suppli et al., studied the microbiome in liver biopsies and blood from healthy lean and obese patients. More

Metabolism and Obesity: the liver microbiome & the development of NAFLD

Apr 6, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work

DOI: 10.1016/j.jhepr.2021.100299 Changes in the liver microbiome as a risk factor for the development of NAFLD in...

Bernard et al. explored the relationship between oral microbiota composition & fat taste sensitivity in obese patients after Vertical Sleeve Gastrectomy. More

Metabolism and Obesity: Oral microbiota and fat taste sensitivity

Apr 5, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work

doi: 10.3389/fnut.2022.1046454The relationship between oral microbiome and fat taste sensitivity in obese patients...

In 2022, Grasset and colleagues, explored the association between the gut-brain-beta cell glucagon-like peptide-1 (GLP-1)-dependent axis, the gut microbiota and the insulin sensitivity. More

Metabolism and T2D: GLP-1 sensitivity is linked with clock genes and ileal microbiome

Mar 22, 2023 | Highlights, Microbiomes & Metabolism, Vaiomer original work

DOI: 10.1007/s00592-021-01790-yAssociation between the gut-brain-beta cell glucagon-like peptide-1(GLP-1)-dependent...

Highlights Articles

Resistance to anti-PD-1 immunotherapy can be attributed to the gut microbiome

Vaiomer is taking part to « la deuxième édition de LA JOURNÉE DU MICROBIOTE»

Gut microbiota dysbiosis contributes to the tumorigenic process, even in extra-intestinal malignancies

Mouse models with human microbiome

Metabolism and obesity: influence of prebiotics, probiotics and symbiotics on microbiomes and liver health

Metabolism and Major Depression: Blood microbiome and metabolome exploration

Metabolism and Obesity: the liver microbiome & the development of NAFLD

Metabolism and Obesity: Oral microbiota and fat taste sensitivity

Metabolism and T2D: GLP-1 sensitivity is linked with clock genes and ileal microbiome

Research

Categorie

Archives

About Vaiomer :

Follow us !